Form 8.3 - Allergan PLC

SAN FRANCISCO--()-- 

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)

Farallon Capital Management, L.L.C. on behalf of funds managed jointly with Farallon Partners, L.L.C

Company dealt in

Allergan PLC

Class of relevant security to which the dealings being disclosed relate (Note 2)

US$0.0001 ordinary shares

 

Date of dealing

14 November 2019

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class ofrelevant security dealt in (Note 3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

7,520,000 2.29

 

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

7,520,000 2.29

 

(b) Interests and short positionsin relevant securitiesof the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

3. DEALINGS (Note 4)

(a) Purchases and sales

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (Note 5)

Purchase

 

85,000

USD 182.0063

 

(b) Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

 

 

 

 

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasingor varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

(ii) Exercising

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

Is a Supplemental Form 8 attached? (Note 9) Yes

Date of disclosure

15 November 2019

Contact name

Caitlin Shreve

Telephone number

+1 415 421 2132

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DETAILS OF OPEN POSITIONS

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

OPEN POSITIONS (Note 1)

Product name,

e.g. call option

Written, or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)

Type, e.g. American, European etc.

Expiry date

Common Shares in AbbVie Inc (Offeror) (ISIN: US00287Y1091)

 

 

-6,512,320

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Notes

  1. Where there are open option positionsor open derivative positions (except for CFDs), full details should be given. Full detailsof any existing agreements to purchase or to sell must also be given on this form.
  2. For all prices and other monetaryamounts, the currencymust be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

Short Name: Farallon Capital Europe
Category Code: RET
Sequence Number: 680344
Time of Receipt (offset from UTC): 20191114T224459+0000

Contacts

Farallon Capital Management, L.L.C.

Contacts

Farallon Capital Management, L.L.C.